USD
$0.00
(0.00%
)At Close (As of Sep 3, 2025)
$1.53B
Market Cap
-
P/E Ratio
-0.8
EPS
$16.73
52 Week High
$5.04
52 Week Low
LIFE SCIENCES
Sector
Field | Value (USD) |
---|---|
Gross Profit | $108M |
Total Revenue | $108M |
Cost Of Revenue | $8.7M |
Costof Goods And Services Sold | $8.7M |
Operating Income | -$110M |
Selling General And Administrative | $59M |
Research And Development | $160M |
Operating Expenses | $219M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $8.7M |
Income Before Tax | -$97M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$97M |
Comprehensive Income Net Of Tax | - |
Ebit | -$110M |
Ebitda | -$102M |
Net Income | -$97M |
Field | Value (USD) |
---|---|
Total Assets | $352M |
Total Current Assets | $320M |
Cash And Cash Equivalents At Carrying Value | $302M |
Cash And Short Term Investments | $302M |
Inventory | - |
Current Net Receivables | $1.4M |
Total Non Current Assets | $32M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $17M |
Other Non Current Assets | - |
Total Liabilities | $143M |
Total Current Liabilities | $111M |
Current Accounts Payable | $16M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $7.6M |
Total Non Current Liabilities | $32M |
Capital Lease Obligations | $25M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $25M |
Other Current Liabilities | $21M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $210M |
Treasury Stock | - |
Retained Earnings | -$1.1B |
Common Stock | $1.2B |
Common Stock Shares Outstanding | $138M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$151M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $8.7M |
Capital Expenditures | $938K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$938K |
Cashflow From Financing | $254M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$97M |
Field | Value (USD) |
---|---|
Gross Profit | $108M |
Total Revenue | $108M |
Cost Of Revenue | $8.7M |
Costof Goods And Services Sold | $8.7M |
Operating Income | -$110M |
Selling General And Administrative | $59M |
Research And Development | $160M |
Operating Expenses | $219M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $8.7M |
Income Before Tax | -$97M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$97M |
Comprehensive Income Net Of Tax | - |
Ebit | -$110M |
Ebitda | -$102M |
Net Income | -$97M |
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes and produces new stereopure oligonucleotides through PRISM, a drug discovery and development platform. The company is headquartered in Singapore.